Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Oral and intranasal aspirin desensitisation for non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease.
Cochrane Database Syst Rev
January 2025
Department of Otorhinolaryngology, Amsterdam University Medical Centre, Amsterdam, Netherlands.
Background: NSAID-exacerbated respiratory disease (N-ERD) is a hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin or ibuprofen, accompanied by chronic rhinosinusitis (with or without nasal polyps) or asthma. The prevalence of hypersensitivity to NSAIDs is estimated to be 2%. The first line of treatment is the avoidance of NSAIDs.
View Article and Find Full Text PDFPredictors of treatment failure of tubal pregnancy with single-dose methotrexate regimen - a systematic review and meta-analysis.
J Obstet Gynaecol
December 2025
Department of Obstetrics and Gynecology, the Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Background: Ectopic pregnancies represent a potentially life-threatening medical emergency, with 95% being tubal. This meta-analysis aimed to identify early predictors for single-dose methotrexate (MTX) treatment failure in tubal pregnancies.
Methods: A literature search was conducted across several databases from their inception to December 2023, with references in the selected studies manually reviewed.
Clinical characteristics and prognostic factors of COVID-19 in rheumatic patients and their family members: a retrospective study.
Front Immunol
January 2025
Department of Rheumatism and Immunity, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Article Synopsis
- Patients with rheumatic diseases tend to recover from COVID-19 faster (average 13 days) compared to their family members (average 16 days), despite being on immunosuppressive treatments.
- The study found that rheumatic patients have a lower risk of developing moderate to severe COVID-19, with pre-infection use of NSAIDs linked to a higher chance of mild cases.
- Patients using disease-modifying anti-rheumatic drugs (DMARDs) before infection were significantly less likely to develop severe cases compared to those who were not on these medications.
Risk factors for methotrexate treatment failure in tubal ectopic pregnancy: a retrospective cohort study.
BMC Pregnancy Childbirth
December 2024
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, People's Republic of China.
Background: Ectopic pregnancy (EP) accounts for approximately 2% of all pregnancies, with tubal ectopic pregnancies (TEPs) being the most common type. Methotrexate (MTX) is a noninvasive and effective medical management option for TEP, but failure rates range from 10 to 36%, posing challenges in clinical practice. Identifying risk factors for MTX treatment failure is crucial to improve patient outcomes and guide clinical decision-making.
View Article and Find Full Text PDFA clinical perspective on muscle specific kinase antibody positive myasthenia gravis.
Front Immunol
December 2024
Department of Neurology, Medical University of Vienna, Vienna, Austria.
The discovery of autoantibodies directed against muscle-specific kinase (MuSK) in "seronegative" myasthenia gravis (MG) patients marked a milestone in MG research. In healthy muscle, MuSK regulates a phosphorylation pathway, which is essential for the development and maintenance of acetylcholine receptor (AChR) clusters at the neuromuscular junction. Autoantibodies directed against MuSK are predominantly of the IgG4 subclass, but there is increasing evidence that IgG1-3 could also contribute to the pathology underlying MuSK-MG.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!